Pancreatic Cancer Research

ResearcherNantong UniversityNo recent work listed

Renfang Mao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8465-1614; OpenAlex author ID A5055646296. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers

Papers 4

  1. Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance. Last author DOI 10.1007/s10637-020-00951-0↗
  2. A super-enhancer controls TGF- β signaling in pancreatic cancer through downregulation of TGFBR2. Co-author DOI 10.1016/j.cellsig.2019.109470↗
  3. Targeting liquid-liquid phase separation in pancreatic cancer. Co-author DOI 10.21037/tcr.2019.01.06↗
  4. Orchestrating a biomarker panel with lncRNAs and mRNAs for predicting survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jcb.27119↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yihui Fan · 4 shared papers, 2018–2020 · strength 0.40
  2. Erhao Zhang · 2 shared papers, 2020 · strength 0.22
  3. Hao Chen · 2 shared papers, 2018–2020 · strength 0.20
  4. Guo-Xiong Zhou · 2 shared papers, 2018–2020 · strength 0.20
  5. Yue Ming · 2 shared papers, 2018–2019 · strength 0.18
  6. Xiaolin Zhu · 1 shared paper, 2020 · strength 0.10
  7. Guoxiong Zhou · 1 shared paper, 2020 · strength 0.10
  8. Jianbo Shen · 1 shared paper, 2020 · strength 0.10
  9. Mingbing Xiao · 1 shared paper, 2020 · strength 0.10
  10. Yingcheng Charles Wu · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.